1. Home
  2. RCUS vs SUPN Comparison

RCUS vs SUPN Comparison

Compare RCUS & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Arcus Biosciences Inc.

RCUS

Arcus Biosciences Inc.

HOLD

Current Price

$25.41

Market Cap

3.1B

Sector

Health Care

ML Signal

HOLD

Logo Supernus Pharmaceuticals Inc.

SUPN

Supernus Pharmaceuticals Inc.

HOLD

Current Price

$45.71

Market Cap

2.6B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RCUS
SUPN
Founded
2015
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
3.1B
2.6B
IPO Year
2018
2012

Fundamental Metrics

Financial Performance
Metric
RCUS
SUPN
Price
$25.41
$45.71
Analyst Decision
Buy
Strong Buy
Analyst Count
8
4
Target Price
$28.88
$63.25
AVG Volume (30 Days)
1.7M
739.6K
Earning Date
10-28-2025
11-04-2025
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$240,000,000.00
$681,539,000.00
Revenue This Year
N/A
$8.32
Revenue Next Year
N/A
$23.36
P/E Ratio
N/A
N/A
Revenue Growth
N/A
4.54
52 Week Low
$6.50
$29.16
52 Week High
$26.40
$57.65

Technical Indicators

Market Signals
Indicator
RCUS
SUPN
Relative Strength Index (RSI) 71.57 45.85
Support Level $24.32 $44.09
Resistance Level $26.40 $47.26
Average True Range (ATR) 1.30 1.27
MACD 0.01 0.23
Stochastic Oscillator 82.78 45.11

Price Performance

Historical Comparison
RCUS
SUPN

About RCUS Arcus Biosciences Inc.

Arcus Biosciences Inc is a clinical-stage biopharmaceutical company. It develops immunotherapies for the treatment of cancer. The company focuses on an ATP-adenosine pathway, which is a key driver of immunosuppression in the tumor microenvironment to create and optimize differentiated small-molecule immuno-oncology product candidates. Its product pipeline includes Domvanalimab, Etrumadenant, AB598, Casdatifan among others. Arcus conducts clinical trials for different types of cancers such as Lung, Colorectal, Pancreatic, and others. The company operates through a single segment which is the business of developing and commercializing immunotherapies.

About SUPN Supernus Pharmaceuticals Inc.

Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, and Osmolex ER.

Share on Social Networks: